Leaves of grass

Half a dozen key posters to watch out for in early stage oncology at SITC22

November 9, 2022

SITC22 Preview 1 – Looking under the hood

6 abstracts to watch out for on how to overcome immune escape

October 12, 2022

Fishing for Gems from the Poster Halls Part 1

Bispecifics come and bispecifics go as companies seek to find a balance

September 29, 2022

ESMO22 Developmental Therapeutics Preview on Immunotherapies

In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…

August 31, 2022

Catamaran Bio sets sail in 2022

Interview with Dr Vipin Suri, CSO Catamaran Bio about the science behind their CAR-NK cell therapy.

July 27, 2022

Shoreline rides the CAR-NK wave at AACR22

First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22

July 7, 2022

Talkin’ ’bout a Revolution

The continuous evolution of BCMA CAR-T cell therapy products and how they are doing

June 6, 2022

Trials and Tribulations

A look at early stage CAR-T cell therapies in development

June 5, 2022

Up and coming cell therapy companies to watch out for

What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?

May 24, 2022

Take the high road

5 abstracts to watch out for at the ASCO22 meeting in Chicago

May 2, 2022


New CAR-T cell developments in solid tumours - hit or miss?

April 24, 2022

An inconvenient truth

Looking beyond the hype from a broader perspective

April 18, 2022

Winner, winner, chicken dinner!

5 key and novel early areas of development which stood out to us at AACR22

April 11, 2022

5 strategies for overcoming challenges to CAR-T cells in solid tumours with CAR-T cells

CAR-T cells have struggled to make an impact in solid tumours, are things changing for the better?

February 14, 2022

Is the future of CAR T cell therapy beyond Oncology?

A look at new and quite unexpected directions for CAR-T cell therapy

February 12, 2022

What’s the next stop in CAR T cell therapy?

Highlights from Day 1 of CART22, part 1

February 11, 2022

Challenges and opportunities with CAR-T cell therapies

Some important new papers on CAR-T cell therapies are shedding light on potential new combination strategies

February 7, 2022

The CAR-T cell therapy merry-go-round in aggressive lymphomas

A look at a major phase 3 trial result and some of the nuances behind the data leading to a negative study

December 14, 2021

Kaizen and the art of improving CAR-T cell performance

Part 2 of our mini-series on Next Generation CAR-T cells

December 14, 2021

A new approach to overcoming CAR-T cell limitations

Overcoming the limitations associated with CAR-T performance and lack of persistence

December 12, 2021

What to watch out for on the CAR-T cell therapy front

Several controversies abound in the CAR-T cell niche this year, plus what's coming next?

December 7, 2021

Can bispecifics succeed where ADCs have failed?

Finessing oncology targets can be both tricky and challenging. Does changing the modality help?

November 23, 2021

New developments in the cell and gene therapy landscape

Novel approaches to fine tuning CAR-T cell therapies are hitting the clinic

November 17, 2021
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021

Making a difference in aggressive lymphomas

Round-up of key highlights relating to CAR-T cell therapies, CELMoDs and super-enhancer activity in DLBCL

June 22, 2021

Advent of a new era in advanced prostate cancer treatment

A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer

June 3, 2021

The Future of Cell and Gene Therapies

13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies

April 22, 2021

Novel approaches to cell therapies – Part 1

A look at switchable CAR-T cell therapies, plus CARs based on alternative immune cells.

April 19, 2021

Highlights and commentary on key AACR21 data presentations

13 talks at AACR21 caught our attention - which ones intrigued or dismayed - and why?

April 13, 2021

Fifteen AACR21 On Demand Presentations To Watch

Noteworthy AACR21 on-demand presentations.

March 23, 2021

Old Dog New Tricks

Exploring a novel approach to overcoming immunotherapy resistance

January 26, 2021

How bispecifics will make an impact in myeloma

Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?

January 13, 2021

Looking through the window at the cilta-cel data

A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed

January 12, 2021

Future of NK Cell Therapy – Part 2

Commentary on engineered NK cells, including CAR-NK and memory-like NK cells

January 6, 2021

Future of NK Cell Therapy – Part 1

Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?

January 5, 2021

ASH Day 1 highlights and lowlights Part 2

Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy

December 6, 2020

Highlights of Saturday at ASH20 Part 1

Commentary on Saturday at ASH20

December 6, 2020

ASH20 CAR-T cell therapy Preview

Rock around the CAR-T cell clock to learn what to watch out for at ASH20!

November 24, 2020

On finding new targets and boosting existing therapies

Science drives oncology new product development and the AACR special conferences are always a good place…

October 22, 2020

Potential new targets and biomarkers for immunotherapy

How we can learn more from failure in clinical trials so we can improve outcomes further with emerging agents in early development

October 20, 2020

Encouraging progress in immunometabolism

Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies

September 1, 2020

A novel approach to enhance adoptive cell therapy

Using CRISPR screens to find new targets for enhancing T cell fitness

August 25, 2020

Potential of Immunometabolism to Enhance CAR T cell therapy

How can we use metabolic reprogramming to enhance CAR T cell therapy?

August 18, 2020

Making a splash in the competitive CAR-T space

If we were to tackle CAR T cell therapy design differently, how would we go about doing it?

July 13, 2020

New developments in CAR-T cell therapies including controversial ones

The ups and downs of CAR-T cell therapy development continues apace

July 8, 2020

Putting NK cells to work

Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...

July 7, 2020

Are gamma delta T cells ready yet for prime time?

Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?

July 1, 2020

Engineering Immunity – what did we learn from ASGCT20?

There are some creative and innovative new CAR T cell therapy designs being developed - what are they and where will they be tested?

May 14, 2020

ASGCT20 Gems from the ePoster Hall

Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20

May 14, 2020

Postcard 2 on Adoptive Cell Therapies from the AACR20 Virtual Meeting

In our latest postcard from AACR20 virtual meeting we take a look at the adoptive cell therapy plenary session

April 28, 2020

One swallow does not a summer make

Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20

April 27, 2020

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020

Alternative cell therapy approaches to tackling cancer

How can we go about improving cell therapy approaches?

March 26, 2020

Unlocking novel IO targets and anti-cancer agents in early development

When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?

March 24, 2020

Under the Radar

An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy

February 28, 2020

Overcoming challenges associated with cell therapy approaches

Insights from Transplantation & Cellular Therapy (TCT) meeting on the next generation of CAR T cells

February 21, 2020

Whipping up a frenzy in CAR-T cell future developments

In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours

February 13, 2020

Quest for the Holy Grail of Cell Therapy

CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."

February 11, 2020

What does the next decade hold for CAR T cell therapy?

Interview with Dr Carl June on what the next decade holds for CAR T cells, cell therapy and genome engineering

February 6, 2020

A delicate question of balance

Interview with Prof John Gribben at second European EHA EBMT CAR T cell therapy meeting in Sitges, Spain

February 5, 2020
Sitges Sunrise

Chasing the Light in Cell Therapy

Commentary on Day 2 of the EHA EBMT 2nd European CAR T cell meeting

February 1, 2020

Shooting for the stars with next generation cell therapies

Commentary on first day of EHA EBMT European CAR T meeting in Sitges, Spain

January 31, 2020

Life, the world, and the cell therapy universe

Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?

January 30, 2020

An up and coming IO company to watch out for

Looking beyond CAR-T cells and checkpoint blockade, there are some promising young companies on the rise to watch out for - here's one of them

January 29, 2020

Eyes on CAR-T Cell Therapy in Europe – Future Directions

There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.

October 17, 2019

Dracarys! How T cell therapy is like Game of Thrones

Is T cell therapy like Game of Thrones?

July 1, 2019

Incysus Targets GBM with Gamma Delta T Cells

Can gamma delta T cells be effective as a therapeutic in GBM?

April 23, 2019

Going beyond BCMA as a target in multiple myeloma

Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.

April 22, 2019

Are 𝞬𝝳 T cells immuno-suppressive and should we delete them?

As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative

April 17, 2019

A tale of 3 cellular therapy companies

A snapshot of 3 UK cell therapy companies, Autolus, Achilles and GammaDelta Therapeutics

March 11, 2019
TC BioPharm Office Building

TC BioPharm leads the way in allogeneic gamma delta T cells

TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020

March 4, 2019

Gamma delta T cell cancer immunotherapy in China

What can we learn about gamma delta T cell cancer immunotherapy in China?

February 28, 2019
Aerial View Thames Estuary

Emerging Gamma Delta T Cell Cancer Immunotherapy Landscape

A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development

February 27, 2019

Are gamma delta T cells the next wave of cell therapies?

Can we make novel allogeneic cell therapies with γδ T cells? We find out!

February 26, 2019

A Voyage of Discovery

Can γδ T cells be employed as a therapeutic against cancer?

February 25, 2019

A novel approach to cell therapy

Beyond T and NK cells, other immune cells can be used for cell therapies in solid tumours

January 4, 2019

Potential of CAR T cell therapy in CLL

How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.

December 10, 2018

SITC18 Preview and IO curiosities

An extensive round-up of what to expect from SITC18 ahead of the abstract reveal

November 2, 2018

Iraj Ali leads the way at Achilles Therapeutics

Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens

October 31, 2018

Update on CAR T cell therapies at CICON18

Some key notes on CAR T cell therapy developments ahead of SITC18 and ASH18

October 3, 2018

Preview of CICON18 – Part 1

Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies

September 20, 2018

New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

Update on BCMA, SLAMF7 and other targets in multiple myeloma

September 11, 2018

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018

Pathways to success with NK cell therapy

Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?

August 28, 2018

Armored CAR-T cell therapies and commercial threats from the East

On launched products, armored CARs and the potential threat from China

August 16, 2018

Adapting TCR therapies for different solid tumours

An in-depth look at Adaptimmune's TCR T cell therapy program

July 10, 2018

Development of Next Generation CAR T cell therapies

A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers

May 14, 2018

An up and coming new player in CAR T cell therapy

A look at path to market strategies open to a small biotech in the CAR-T cell space

May 9, 2018

How Charles Swanton plans to revolutionize treatment of Lung and Renal cancers

What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...

April 26, 2018

Exploring Gamida Cell with Dr Julian Adams

A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...

March 15, 2018

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018

A look at NK cells – an interview with Dr Michael Caligiuri

A look at the history of NK cell development and where we're going in future with this IO approach

March 7, 2018

Challenges and Opportunities with NK cells for cancer therapeutics

Our latest primer explores NK cells and their role in oncology R&D - it's an up and coming area

March 5, 2018

Potential of Exosomes in Pancreatic Cancer

A look at an emerging area for biomarkers and stealth cancer therapeutics

March 1, 2018

Are fast or slow CARs better for the future?

In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space

February 26, 2018

Future of CAR T Cell Therapy for Leukemia and Lymphoma

What did Dr Grupp and Dr Komanduri learn from participation in the CAR T cell therapy trials?

February 22, 2018

How Will Adoptive Cell Therapy Crack Solid Tumours?

A look at Dr Malcolm Brenner's work on virus specific T cell therapies

January 31, 2018

Bad news for Bellicum and BPX-501

FDA places Bellicum's BPX-501 on clinical hold - what's the story and what's next?

January 30, 2018

How Obsidian could revolutionise CAR T cell therapy in solid tumours

A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours

January 10, 2018

A competitive threat to CAR T cell therapy in aggressive lymphoma

New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment

January 3, 2018

ASH17 CAR T cell therapy Preview

A look at what's hot in CAR T cell therapies at #ASH17

December 4, 2017

Interview with Dr Stephan Grupp on the JCAR015 ROCKET trial

A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset

November 11, 2017

Update on CD123 and other viable targets in AML

With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?

October 17, 2017

Targeting Natural Killer Cells in Cancer Immunotherapy

Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?

October 11, 2017

How to disrupt the CAR T cell therapy space

Is the CAR T cell therapy space ready for disruption? At least one researcher thinks so. What does this entail?

September 21, 2017

Is CD123 a good target in AML?

A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.

August 31, 2017

The dawn of a new beginning for Cellectis?

What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?

August 30, 2017

Waseem Qasim Pioneers Allogeneic CAR T Cell Therapy

Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?

August 29, 2017

Novartis JULIET trial and other CAR-T cell issues

A look at the initial results from the Novartis CTL019 pivotal trial in aggressive lymphoma (JULIET).

June 8, 2017
Chicago River

ASCO 2017 CAR T Cell Therapy Preview

Some intriguing surprises in the CAR T cell therapy abstracts this year...

May 24, 2017

On Gritstone and neoantigens

A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?

May 4, 2017

Potential of CAR T cell therapy targeting Glioblastoma

Encouraging new developments in GBM with a novel CAR T cell therapy

April 18, 2017

JCAR015 is dead. Long live JCAR015

After a rocky 2016, what does 2017 hold for Juno as they switch focus from JCAR015 to JCAR017?

March 1, 2017

The future of CAR T cells in pediatric ALL

Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL

January 9, 2017

Post ASH16 Reader Q+A on CAR T cell therapies

We answer more questions on CAR T cell therapies and ADCs in acute leukemias from ASH

December 16, 2016

ASH16 Update on BCMA CAR T cell therapies

A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma

December 14, 2016

Juno plays Russian Roulette with JCAR015

A most unfortunate follow-up to the ongoing safety issues with Juno's JCAR015 and neurotoxicity in the run-up to #ASH16

November 23, 2016

ASH16 Preview of CAR T Cell Therapies

What To Watch Out For in CAR T Cell Therapies at ASH in San Diego in December 2016

November 7, 2016

Glycomics The Third Language of Life

How will glycomics impact cancer research? Some interesting new developments are emerging in this field

October 27, 2016

What are neoantigens and why do they matter in cancer immunotherapy?

A primer on neoantigens and their importance in cancer research

August 9, 2016

New developments in allogeneic cellular therapies

Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?

August 5, 2016

Biotech Mailbag – Jounce & the CAR T Race to Market

July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...

July 27, 2016

JUNO setback by Patient Deaths due to CAR T Cell Neurotoxicity

Juno ROCKET trial put on clinical hold following 3 death due to cerebral edema. What's the skinny?

July 7, 2016

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016

George Coukos Drives Novel Ovarian Cancer Immunotherapies Forward

How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!

May 16, 2016

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016

Making CAR T cell therapy more effective in leukemia and solid tumors

Finding new ways to optimise CAR T cell therapy in CLL and solid tumours may be closer than you think...

March 15, 2016

Could a Novel Cell Therapy replace CAR T Cell Therapy?

Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy

March 1, 2016

Optimizing CD19 CAR T Cell Therapy

Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy

February 23, 2016

Challenges and Opportunities of CAR T Cell Therapy in CLL

Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL

February 19, 2016

Will Unum’s approach take the CAR T cell therapy market by storm?

Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?

February 4, 2016

Immunotherapy for Lymphoma using T cells Targeting Multiple Tumor-Associated Antigens

A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.

February 3, 2016

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015

Q&A on hot topics in CAR T cell therapies

Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies

November 18, 2015

Strategies to overcome CAR T cell therapy resistance

Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance

November 12, 2015

Do Cellectis CAR T Cells Really Work?

Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL

November 10, 2015

Immunocore ImmTAC TCR platform offers combination promise

Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.

September 14, 2015

Adoptive Cell Therapies – an interview with Dr Carl June

Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours

August 14, 2015

Adoptive Cell Therapy: An Interview with Dr Steven Rosenberg

We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...

August 12, 2015
Dr William Pao Roche

Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?

Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.

July 1, 2015

Juno and Celgene’s unexpected CAR-T cell and TCR collaboration

Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?

June 30, 2015

UCL Drives CD19 CAR T Cell Therapy Forward in Europe

University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.

April 14, 2015

Will CAR-T cells make an impact in solid tumours?

Novel targets are emerging in urothelial bladder cancer which may offer new therapeutic options for antibody and CAR-T cell therapy development.

March 25, 2015

Cellular therapy with EBV-CTL reduces death post stem cell transplant

What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?

March 20, 2015

CAR-T and Gene Therapy excite BMT Tandem Meeting

Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.

February 25, 2015

CAR-T Cell Therapies from China are a Competitive Threat

Cellular Biomedicine Group (NASDAQ: CBMG) has acquired rights to the Chimeric Antigen Receptor T cell (CAR-T) therapy of the PLA General Hospital in Beijing.

February 11, 2015

The application of TILs, CARs and TCRs in cancer research

What does the evolving landscape for CAR, TIL and TCR cell therapies look like?

February 10, 2015

Tumour infiltrating lymphocytes TILs: what are they and why do they matter?

The NCI have been at the forefront of developing novel cancer immunotherapies for several decades, but what is the current status of their groundbreaking work? Find out more in this primer on TILs.

February 5, 2015

Bellicum moves BPX-501 T Cell Therapy forward $BLCM

What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.

January 13, 2015

Cellectis ramps up CAR-T development in 2015

What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?

January 6, 2015

Challenge of Cytokine Release Syndrome in CD19 CAR-T Cell Therapy

At the Society for Immunotherapy of Cancer (SITC) meeting last week, one of the Hot Topic sessions that took place after the conference formally ended was in managing the toxicities associated with chimeric antigen receptor T cell (CAR-T) therapy.

November 17, 2014
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014

The real story behind Juno’s CAR T cell therapy suspensions

This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.

April 6, 2014

Will CAR T cells give new therapies for NHL and CLL a run for their money?

Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas

March 6, 2014

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014

Juno Therapeutics takes on Penn in dispute over St Jude Chimeric Antigen Receptor Patent

Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.

January 6, 2014

Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens

Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.

December 13, 2013

ASH 2012: CTL019 chimeric antigen receptor technology emerging as a new leukemia treatment

For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

January 15, 2013